A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

J Bone Miner Res. 2015 Feb;30(2):216-24. doi: 10.1002/jbmr.2351.

These results support further study of blosozumab as a potential anabolic therapy for osteoporosis.

Autor: ReckerRR,BensonCT,MatsumotoT,BologneseMA,RobinsDA,A J,ChiangAY,Hu L,Krege JH, Sowa H,Mitlak BH,M SL
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen